DIVIGEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIVIGEL (DIVIGEL).
Estradiol replacement therapy; binds to estrogen receptors, activating transcription of estrogen-responsive genes, leading to proliferation of endometrial and breast epithelium, and modulation of gonadotropin secretion.
| Metabolism | Primarily hepatic metabolism via CYP3A4; also undergoes conjugation (glucuronidation) and sulfation; enterohepatic recirculation. |
| Excretion | Urine (approximately 90-95% as glucuronide and sulfate conjugates, with less than 5% as unchanged drug); feces (approximately 5-10% via biliary excretion) |
| Half-life | Terminal elimination half-life of estradiol is 13-15 hours; clinical context: due to enterohepatic recirculation, serum levels may fluctuate; transdermal delivery avoids first-pass hepatic metabolism, resulting in more stable levels |
| Protein binding | 98-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin |
| Volume of Distribution | Vd approximately 1-2 L/kg, indicating extensive distribution into tissues; clinical meaning: reflects wide distribution to target organs such as breast, uterus, and adipose tissue |
| Bioavailability | Transdermal gel: approximately 10-20% of the applied dose (due to incomplete absorption and retention in the skin depot); avoids first-pass hepatic metabolism, thus effective at lower doses compared to oral |
| Onset of Action | Transdermal gel: detectable serum estradiol levels within 15-30 minutes; clinical effects (e.g., vasomotor symptom relief) may be observed within 1-2 weeks |
| Duration of Action | After single application, serum estradiol returns to baseline within 24-48 hours; clinical effects for hormone replacement require continuous daily application; steady-state achieved by day 3-5 |
Transdermal gel: 0.25-1.0 g applied once daily to upper thigh, abdomen, or upper arm. Each gram contains 1 mg estradiol.
| Dosage form | GEL |
| Renal impairment | No specific dose adjustment recommended based on GFR; estradiol is not significantly renally cleared. |
| Liver impairment | Contraindicated in severe hepatic dysfunction (Child-Pugh class C). In mild to moderate (Child-Pugh A/B), use with caution and monitor. |
| Pediatric use | Not FDA-approved for use in children; efficacy and safety not established. |
| Geriatric use | Use lowest effective dose; consider increased risk of thromboembolic events, cardiovascular disease, and dementia in women >65 years. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DIVIGEL (DIVIGEL).
| Breastfeeding | Estradiol is excreted into human breast milk in small amounts. The M/P ratio is not specifically reported for Divigel; however, estradiol levels in milk are low. Effects on the nursing infant are not well studied, but potential for adverse effects exists. Divigel is not recommended during breastfeeding. |
| Teratogenic Risk | Divigel (estradiol) is contraindicated in pregnancy. Estrogens are associated with an increased risk of congenital anomalies, including cardiovascular and urogenital defects, when used during the first trimester. In the second and third trimesters, exposure may cause feminization of male fetuses, functional genital tract abnormalities, and potential long-term reproductive effects. Use is not recommended at any stage. |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer in women with an intact uterus. Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia. Increased risk of venous thromboembolism, stroke, and possibly dementia. Estrogen plus progestin has been associated with increased risk of breast cancer, stroke, VTE, and dementia.
| Serious Effects |
Undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active or history of venous thromboembolism; active or history of arterial thromboembolism; known anaphylactic reaction or angioedema to estradiol; known liver impairment or disease; known protein C, protein S, or antithrombin deficiency; known thrombophilic disorders; pregnancy; hypersensitivity to any ingredient.
| Precautions | Cardiovascular disorders (e.g., coronary heart disease, stroke, VTE), malignant neoplasms (endometrial cancer, breast cancer), gallbladder disease, hypercalcemia, fluid retention, elevated blood pressure, hereditary angioedema, hypertriglyceridemia, hepatic hemangiomas, exacerbation of endometriosis, severe hypocalcemia in hypoparathyroidism, and thyroid hormone effects. |
Loading safety data…
| Fetal Monitoring | If inadvertent exposure during pregnancy occurs, monitor fetal development with ultrasound for structural anomalies. No specific monitoring is required for Divigel therapy as it is contraindicated in pregnancy. |
| Fertility Effects | Exogenous estrogens may suppress ovulation and impair fertility during use. Reversible upon discontinuation. Long-term effects on fertility are not well documented. |